| [1] | Committee of Integrated Rehabilitation for Urogenital Tumors, Chinese Anti-Cancer Association. 
														
															Chinese expert consensus on perioperative integrated rehabilitation for radical prostatectomy (2024 edition)
														[J]. China Oncology, 2024, 34(9): 890-902. | 
																																																																																
													| [2] | PAN Jian, YE Dingwei, ZHU Yao, WANG Beihe. 
														
															Correlation analysis of PSMA PET/CT-derived parameters and circulating tumor DNA features in patients with hormone-sensitive prostate cancer
														[J]. China Oncology, 2024, 34(7): 680-685. | 
																																																																																
													| [3] | Cancer Nuclear Medicine Committee of China Anti-Cancer Association, Chinese Association of Nuclear Medicine Physicians. 
														
															Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)
														[J]. China Oncology, 2024, 34(7): 702-714. | 
																																																																																
													| [4] | PAN Jian, ZHU Yao, DAI Bo, YE Dingwei. 
														
															Advances in basic research, clinical diagnosis and treatment of prostate cancer in 2022
														[J]. China Oncology, 2023, 33(3): 210-217. | 
																																																																																
													| [5] | Society of Male Reproductive System Oncology, China Anti-Cancer Association. 
														
															Expert consensus on perioperative comprehensive treatment for high risk prostate cancer (2023 edition)
														[J]. China Oncology, 2023, 33(12): 1204-1214. | 
																																																																																
													| [6] | YANG Wenbo, ZHANG Bin, WU Jiahui, CUI Jie. 
														
															Current status and treatment direction of the immune microenvironment of castration-resistant prostate cancer
														[J]. China Oncology, 2023, 33(10): 945-953. | 
																																																																																
													| [7] | ZHOU Shukui, ZHANG Dongliang, WANG Xiang, LIU Lei, LI Zeng, YANG Shengke, LIAO Hong. 
														
															Developing a new animal model of subcutaneous transplanted prostate cancer with cell sheet technology
														[J]. China Oncology, 2022, 32(3): 200-206. | 
																																																																																
													| [8] | ZHOU Bingni, LIU Xiaohang, GU Bingxin, ZHOU Liangping, GU Yajia. 
														
															The value of mpMRI combined with 99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy
														[J]. China Oncology, 2022, 32(2): 134-141. | 
																																																																																
													| [9] | Chinese Prostate Cancer Consortium (CPCC), YE Dingwei, HUANG Jian. 
														
															Chinese Prostate Cancer Consortium (CPCC) Chinese expert consensus on advanced prostate cancer: clinical management of patients with metastatic hormone-sensitive prostate cancer treated by initial novel hormone therapy (2022 edition)
														[J]. China Oncology, 2022, 32(12): 1242-1258. | 
																																																																																
													| [10] | XU Wenhao, TIAN Xi, Aihetaimujiang·Anwaier , QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. 
														
															A systematic review of current advancements of artificial intelligence in genitourinary cancers
														[J]. China Oncology, 2022, 32(1): 68-74. | 
																																																																																
													| [11] | WEI Yu , ZHANG Tingwei , HE Yi , LI Jun , BI Jianbin , ZENG Yu , WAN Lijun , WU Gaoliang , WANG Huansheng , ZHANG Jun , ZHU Wei , QU Yuanyuan , ZHU Yao , YE Dingwei . 
														
															Preliminary study on efficacy and safety of fluzoparib in patients with metastatic castration-resistant prostate cancer
														[J]. China Oncology, 2021, 31(7): 561-566. | 
																																																																																
													| [12] | CAO Dalong, ZHU Wenkai, SHI Guohai, ZHANG Hailiang, WANG Ziliang, YE Dingwei. 
														
															The influence of PRUNE2 gene point mutation on proliferation, apoptosis, invasion and migration of prostate cancer DU145 cells
														[J]. China Oncology, 2021, 31(6): 441-446. | 
																																																																																
													| [13] | WANG Zhu, ZHANG Ying, ZHANG Jianwen, DENG Qiong, LIANG Hui. 
														
															Nuclear receptor HNF4α promotes castration-resistant prostate cancer via its regulation of androgen receptor expression
														[J]. China Oncology, 2021, 31(3): 170-175. | 
																																																																																
													| [14] | BIAN Xiaojie, YE Dingwei. 
														
															New ideas of androgen deprivation therapy for prostate cancer: new progress in clinical research of testosterone maximum control
														[J]. China Oncology, 2021, 31(12): 1209-1214. | 
																																																																																
													| [15] | PAN Jian, WEI Yu, YE Dingwei, ZHU Yao. 
														
															Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
														[J]. China Oncology, 2021, 31(11): 1104-1109. |